A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic ; volume:271 ; number:9 ; day:27 ; month:6 ; year:2024 ; pages:5813-5824 ; date:9.2024
Journal of neurology ; 271, Heft 9 (27.6.2024), 5813-5824, 9.2024
- Urheber
-
Lal, Anoushka P.
Foong, Yi Chao
Sanfilippo, Paul G.
Spelman, Tim
Rath, Louise
Levitz, David
Fabis-Pedrini, Marzena
Foschi, Matteo
Habek, Mario
Kalincik, Tomas
Roos, Izanne
Lechner-Scott, Jeannette
John, Nevin
Soysal, Aysun
D’Amico, Emanuele
Gouider, Riadh
Mrabet, Saloua
Gross-Paju, Katrin
Cárdenas-Robledo, Simón
Moghadasi, Abdorreza Naser
Sa, Maria Jose
Gray, Orla
Oh, Jiwon
Reddel, Stephen
Ramanathan, Sudarshini
Al-Harbi, Talal
Altintas, Ayse
Hardy, Todd A.
Ozakbas, Serkan
Alroughani, Raed
Kermode, Allan G.
Surcinelli, Andrea
Laureys, Guy
Eichau, Sara
Prat, Alexandre
Girard, Marc
Duquette, Pierre
Hodgkinson, Suzanne
Ramo-Tello, Cristina
Maimone, Davide
McCombe, Pamela
Spitaleri, Daniele
Sanchez-Menoyo, Jose Luis
Yetkin, Mehmet Fatih
Baghbanian, Seyed Mohammad
Karabudak, Rana
Al-Asmi, Abdullah
Jakob, Gregor Brecl
Khoury, Samia J.
Etemadifar, Masoud
Pesch, Vincent van
Buzzard, Katherine
Taylor, Bruce
Butzkueven, Helmut
Walt, Anneke Van der
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-024-12518-7
- URN
-
urn:nbn:de:101:1-2411212132501.096871543863
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lal, Anoushka P.
- Foong, Yi Chao
- Sanfilippo, Paul G.
- Spelman, Tim
- Rath, Louise
- Levitz, David
- Fabis-Pedrini, Marzena
- Foschi, Matteo
- Habek, Mario
- Kalincik, Tomas
- Roos, Izanne
- Lechner-Scott, Jeannette
- John, Nevin
- Soysal, Aysun
- D’Amico, Emanuele
- Gouider, Riadh
- Mrabet, Saloua
- Gross-Paju, Katrin
- Cárdenas-Robledo, Simón
- Moghadasi, Abdorreza Naser
- Sa, Maria Jose
- Gray, Orla
- Oh, Jiwon
- Reddel, Stephen
- Ramanathan, Sudarshini
- Al-Harbi, Talal
- Altintas, Ayse
- Hardy, Todd A.
- Ozakbas, Serkan
- Alroughani, Raed
- Kermode, Allan G.
- Surcinelli, Andrea
- Laureys, Guy
- Eichau, Sara
- Prat, Alexandre
- Girard, Marc
- Duquette, Pierre
- Hodgkinson, Suzanne
- Ramo-Tello, Cristina
- Maimone, Davide
- McCombe, Pamela
- Spitaleri, Daniele
- Sanchez-Menoyo, Jose Luis
- Yetkin, Mehmet Fatih
- Baghbanian, Seyed Mohammad
- Karabudak, Rana
- Al-Asmi, Abdullah
- Jakob, Gregor Brecl
- Khoury, Samia J.
- Etemadifar, Masoud
- Pesch, Vincent van
- Buzzard, Katherine
- Taylor, Bruce
- Butzkueven, Helmut
- Walt, Anneke Van der
- SpringerLink (Online service)
Ähnliche Objekte (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Lithium as a disease-modifying agent for prion diseases
Current experimental disease-modifying therapeutics for multiple system atrophy
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening